S. Toprak, S. Ocal, B. Erismis, E. Yıldırım, R. Altun, S. Karakuş, I. Tek, P. Topçuoğlu
{"title":"VAD联合长春新碱、阿霉素和地塞米松化疗后急性胰腺炎一例新诊断的多发性骨髓瘤患者","authors":"S. Toprak, S. Ocal, B. Erismis, E. Yıldırım, R. Altun, S. Karakuş, I. Tek, P. Topçuoğlu","doi":"10.5580/2b68","DOIUrl":null,"url":null,"abstract":"Background/Aims: The frequency of drug-related gastrointestinal adverse effects, including pancreatitis, has increased with the development and use of chemotherapeutic agents. Methods: In our country, a combination of vincristine, doxorubicin, and dexamethasone is frequently used as the first line of therapy in newly diagnosed multiple myeloma. A case with acute pancreatitis that we believe to depend on this therapy is presented. Results: In this case, after treatment of the acute pancreatitis episode in a very dynamic process, a proteasome inhibitor and following high dose chemotherapy with melphalan were used for the primary disease. Currently the patient is under follow-up at remission. Conclusion: It is important to consider chemotherapeutic agents as a possible etiology for acute pancreatitis in patients presenting with gastrointestinal symptoms, even after a few exposures to the agent.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Acute Pancreatitis Following VAD Chemotherapy Combination Consisting Of Vincristine, Doxorubicin, And Dexamethasone In A Newly Diagnosed Multiple Myeloma Patient: A Case Report.\",\"authors\":\"S. Toprak, S. Ocal, B. Erismis, E. Yıldırım, R. Altun, S. Karakuş, I. Tek, P. Topçuoğlu\",\"doi\":\"10.5580/2b68\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background/Aims: The frequency of drug-related gastrointestinal adverse effects, including pancreatitis, has increased with the development and use of chemotherapeutic agents. Methods: In our country, a combination of vincristine, doxorubicin, and dexamethasone is frequently used as the first line of therapy in newly diagnosed multiple myeloma. A case with acute pancreatitis that we believe to depend on this therapy is presented. Results: In this case, after treatment of the acute pancreatitis episode in a very dynamic process, a proteasome inhibitor and following high dose chemotherapy with melphalan were used for the primary disease. Currently the patient is under follow-up at remission. Conclusion: It is important to consider chemotherapeutic agents as a possible etiology for acute pancreatitis in patients presenting with gastrointestinal symptoms, even after a few exposures to the agent.\",\"PeriodicalId\":22534,\"journal\":{\"name\":\"The Internet Journal of Oncology\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Internet Journal of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5580/2b68\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Internet Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5580/2b68","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Acute Pancreatitis Following VAD Chemotherapy Combination Consisting Of Vincristine, Doxorubicin, And Dexamethasone In A Newly Diagnosed Multiple Myeloma Patient: A Case Report.
Background/Aims: The frequency of drug-related gastrointestinal adverse effects, including pancreatitis, has increased with the development and use of chemotherapeutic agents. Methods: In our country, a combination of vincristine, doxorubicin, and dexamethasone is frequently used as the first line of therapy in newly diagnosed multiple myeloma. A case with acute pancreatitis that we believe to depend on this therapy is presented. Results: In this case, after treatment of the acute pancreatitis episode in a very dynamic process, a proteasome inhibitor and following high dose chemotherapy with melphalan were used for the primary disease. Currently the patient is under follow-up at remission. Conclusion: It is important to consider chemotherapeutic agents as a possible etiology for acute pancreatitis in patients presenting with gastrointestinal symptoms, even after a few exposures to the agent.